Novel cell therapy may improve heart failure symptoms: Study Shows


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Novel cell therapy may improve heart failure symptoms: Study Shows
The cutting-edge treatments for heart failure that may be a good option for these patients

The COVID-19 pandemic has left many people with serious medical conditions, such as heart failure, feeling fearful about coming into the hospital for treatment. A recent study showed a 40 per cent drop in patients seeking medical care for serious heart attacks over the last few months. If left unaddressed, the condition may turn into heart failure, which may limit treatment options even further. Doctors are urging patients not to delay treatment.The good news is that clinical trials for heart disease are underway, studying cutting-edge treatments for heart failure that may be a good option for these patients.

One such treatment being studied uses a patient’s own cells to promote healing of the heart after a heart attack that has progressed to heart failure. The CardiAMP cell therapy is designed for patients suffering from heart failure who feel tired and breathless despite taking regular medications, and who have had to limit their everyday activities as a result. Previously published studies of this type of cell therapy have shown meaningful and sustained improvements in quality of life and heart function for patients with few risks.

"Heart failure patients who continue to have symptoms despite a course of optimal medications often seek a minimally invasive treatment as an alternative to open heart surgery. We look forward to studying the potential of this cell therapy to improve heart function and quality of life," said Dr Natasha Altman, cardiologist and principal investigator of the CardiAMP Heart Failure Trial at UC Health University of Colorado Hospital.

For the treatment, doctors extract cells from a patient’s own bone marrow, process them at the point of care and deliver them to the damaged area of the heart in a minimally invasive cardiac catheterization procedure. Researchers emphasize that the bone marrow cells do not turn into new heart tissue cells; instead, they are designed to stimulate the body’s natural healing process in the heart.

Pete Hagerstrom, a 73-year-old from Colorado Springs who had a previous quadruple bypass to treat his heart failure, was the first patient in his state enrolled in the ongoing USFDA-approved clinical study of the therapy.Participants who qualify for the study are randomly placed into a treatment group or a control group. While Mr. Hagerstrom will not know until the end of the study if he received the cell therapy, he feels better after participating in the trial.

"Everything is easier. I can walk three miles in about 45 minutes, and it takes a lot less time to garden and shovel snow."The CardiAMP Heart Failure Trial will include up to 260 patients at 40 medical centers nationwide.Unlike similar studies, this trial tests a patient’s bone marrow before treatment, in order to identify those patients who are most likely to benefit from treatment. Patients may be candidates for the CardiAMP Heart Failure Trial if they have heart failure as a result of an earlier heart attack and have symptoms that are classified as New York Heart Association Class II or III.

Tags : #HeartPatients #LatestResearchonHeartFailureTreatment14thDec #LatestPharmaNews14thDec #BoneMarrowTreatment #CardiAMPCellTherapy #COVID-19Pandemic

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026